Satsuma Pharmaceuticals Inc (STSA) Stock Price, Quote, News and Overview
NASDAQ:STSA - Nasdaq - US80405P1075 - Common Stock - Currency: USD
STSA Quote, Performance and Key Statistics
1.1
-0.01 (-0.9%)
The current stock price of STSA is 1.1 USD. In the past month the price increased by 2.8%. In the past year, price decreased by -67.46%.
STSA Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 67.21 | 829.40B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 27.44 | 390.99B | ||
| JNJ | JOHNSON & JOHNSON | 16.25 | 390.76B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 20.56 | 230.17B | ||
| MRK | MERCK & CO. INC. | 11.71 | 226.40B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.77 | 215.98B | ||
| PFE | PFIZER INC | 8.46 | 149.04B | ||
| SNY | SANOFI-ADR | 13.58 | 136.54B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 48.97 | 113.23B | ||
| GSK | GSK PLC-SPON ADR | 7.78 | 74.77B | ||
| ZTS | ZOETIS INC | 27.1 | 72.39B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.95 | 44.58B |
Related stock screener links
About STSA
Company Profile
Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Durham, North Carolina and currently employs 25 full-time employees. The company went IPO on 2019-09-13. The firm is focused on developing a therapeutic product for the acute treatment of migraine. The firm's product candidate, STS101, is a drug-device combination of a dry-powder formulation of dihydroergotamine mesylate (DHE), which is designed to self-administered with a pre-filled, single-use, nasal delivery device. STS101 also incorporates an improved 2nd-generation nasal delivery device. STS101 is specifically designed to deliver the clinical advantages of DHE while overcoming its shortcomings.
Company Info
Satsuma Pharmaceuticals Inc
4819 Emperor Boulevard, Suite 340
Durham NORTH CAROLINA 64080 US
CEO: John Kollins
Employees: 25
Company Website: https://www.satsumarx.com/
Phone: 14155050809.0
Satsuma Pharmaceuticals Inc / STSA FAQ
What is the stock price of Satsuma Pharmaceuticals Inc today?
The current stock price of STSA is 1.1 USD. The price decreased by -0.9% in the last trading session.
What is the ticker symbol for Satsuma Pharmaceuticals Inc stock?
The exchange symbol of Satsuma Pharmaceuticals Inc is STSA and it is listed on the Nasdaq exchange.
On which exchange is STSA stock listed?
STSA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for Satsuma Pharmaceuticals Inc stock?
11 analysts have analysed STSA and the average price target is 2.04 USD. This implies a price increase of 85.45% is expected in the next year compared to the current price of 1.1. Check the Satsuma Pharmaceuticals Inc stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is Satsuma Pharmaceuticals Inc worth?
Satsuma Pharmaceuticals Inc (STSA) has a market capitalization of 36.47M USD. This makes STSA a Nano Cap stock.
How many employees does Satsuma Pharmaceuticals Inc have?
Satsuma Pharmaceuticals Inc (STSA) currently has 25 employees.
What are the support and resistance levels for Satsuma Pharmaceuticals Inc (STSA) stock?
Satsuma Pharmaceuticals Inc (STSA) has a support level at 1.04. Check the full technical report for a detailed analysis of STSA support and resistance levels.
Should I buy Satsuma Pharmaceuticals Inc (STSA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of STSA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of STSA, evaluating the profitability, health, valuation and growth aspects
- Satsuma Pharmaceuticals Inc (STSA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- Satsuma Pharmaceuticals Inc (STSA) Sales and EPS estimates to see what analysts future expectations are.
- Satsuma Pharmaceuticals Inc (STSA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- Satsuma Pharmaceuticals Inc (STSA) Insider and Institutional Ownership to learn about the owners and their transactions.
- Satsuma Pharmaceuticals Inc (STSA) Stock Chart to make your own analysis
- Satsuma Pharmaceuticals Inc (STSA) Latest news and press-releases to stay up to date.
Does Satsuma Pharmaceuticals Inc (STSA) stock pay dividends?
STSA does not pay a dividend.
When does Satsuma Pharmaceuticals Inc (STSA) report earnings?
Satsuma Pharmaceuticals Inc (STSA) will report earnings on 2023-08-07, after the market close.
What is the Price/Earnings (PE) ratio of Satsuma Pharmaceuticals Inc (STSA)?
Satsuma Pharmaceuticals Inc (STSA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.01).
STSA Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to STSA. When comparing the yearly performance of all stocks, STSA is a bad performer in the overall market: 86.86% of all stocks are doing better.
STSA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to STSA. STSA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
STSA Financial Highlights
Over the last trailing twelve months STSA reported a non-GAAP Earnings per Share(EPS) of -2.01. The EPS decreased by -12.92% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
STSA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 76% to STSA. The Buy consensus is the average rating of analysts ratings from 11 analysts.